7 news items
ImmunityBio Announces 2024 Annual Meeting of Stockholders with Company Update
IBRX
7 Jun 24
and timing thereof, market and prevalence data, potential benefits to patients, potential treatment outcomes for patients, the described mechanism
Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast
IBRX
17 May 24
and prevalence data, potential benefits to patients, potential treatment actions for patients, the described mechanism of action and results and contributions
ImmunityBio, Serum Institute Of India Agree On An Exclusive Arrangement For Global Supply Of Bacillus Calmette-Guerin Across All Cancer Types
IBRX
2 May 24
to ensure availability of BCG for all approved indications that benefit from ANKTIVA's triangle offense of natural killer cells, T cells, and memory T
ImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer Types
IBRX
2 May 24
indications that benefit from ANKTIVA's triangle offense of natural killer cells, T cells, and memory T cells
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
IBRX
25 Apr 24
, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom
q0h5puqb6isrs8k0t44qae35qzaj9i1t2zbom7511vpsw2bgy1bgatnknfcw
IBRX
22 Apr 24
of the United States, the regulatory review process and timing thereof, market and prevalence data, potential benefits to patients, potential treatment
p2o1vmp9g99nyzkhqr35med3jz6dql3oxoequn8nlet6m1kvid6qk9rrutd
ACRS
IBRX
NUVB
14 Mar 24
and maximizes the potential of pelareorep-based combination therapies to benefit pancreatic cancer patients
- Prev
- 1
- Next